Radioresistance of KRAS/TP53-Mutated Lung Cancer can be overcome by Radiation Dose Escalation or EGFR Tyrosine Kinase Inhibition In Vivo

Recent clinical data have linked KRAS/TP53 co-mutation (mut) to resistance to radiotherapy (RT), but supporting laboratory in vivo evidence is lacking. In addition, the ability of different radiation doses, with/without epidermal growth factor receptor (EGFR)-directed treatment, to achieve local tum...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Int J Cancer
Autori principali: Gurtner, Kristin, Kryzmien, Zofia, Koi, Lydia, Wang, Meng, Benes, Cyril H., Hering, Sandra, Willers, Henning, Baumann, Michael, Krause, Mechthild
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2019
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7440664/
https://ncbi.nlm.nih.gov/pubmed/31359406
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.32598
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi